# US 2026/0097059 A1 · Processes and compositions with antibacterial properties for the treatment of demodex blepharitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097059 A1
- Document ID: US20260097059A1
- Status: Published application
- Kind: A1
- Application number: 19/040,993
- Filed: 2025-01-30
- Published: 2026-04-09
- Earliest claimed: 2024-10-03
- Inventors: Rolando Toyos
- Web page: https://patentgrep.com/patent/US20260097059A1

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61P 17/00: Drugs for dermatological disorders
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compositions for the prevention and treatment of demodex blepharitis in a subject and processes of treatment or prevention of demodex blepharitis. The compositions may include at least one avermectin compound selected from 5-O-demethyl-22,23-dihydroavermectin A1a or 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, or a combination thereof, and melatonin, wherein an aggregate concentration of the avermectin compound is optionally less than 1 wt %. Further devices are provided that include wipe including a woven or non-woven membrane and a treatment composition, the treatment composition including melatonin, one or more anti-microbial compounds, and optionally one or more pharmaceutically acceptable excipients and processes of treatment or prevention of demodex blepharitis in a subject using the wipe, alone or optionally further with the composition as provided herein.

## Claims

### Claim 1

A process for treatment or prevention of demodex blepharitis comprising:
administering to a subject in need thereof a composition comprising:
at least one avermectin compound selected from 5-O-demethyl-22,23-dihydroavermectin A1a, 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, or a combination thereof, and
melatonin,
wherein an aggregate concentration of the avermectin compound is less than 1 wt %.

### Claim 2 (depends on 1)

The process of claim 1, wherein the composition further comprises one or more pharmaceutically acceptable excipients.

### Claim 3 (depends on 1)

The process of claim 1, wherein said melatonin is present at about 0.1 wt % to about 5 wt %.

### Claim 4 (depends on 1)

The process of claim 1, wherein the avermectin compound comprises a combination of 5-O-demethyl-22,23-dihydroavermectin A1a and 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a.

### Claim 5 (depends on 4)

The process of claim 4, wherein the combination is about 90 mol % 5-O-demethyl-22,23-dihydroavermectin A1a and about 10 mol % 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a.

### Claim 6 (depends on 1)

The process of claim 1, wherein the aggregate concentration is less than about 0.5 wt %.

### Claim 7 (depends on 1)

The process of claim 1, wherein the aggregate concentration is about 0.1 wt %.

### Claim 8 (depends on 1)

The process of claim 1, wherein said administering occurs once daily.

### Claim 9 (depends on 1)

The process of claim 1, wherein said administering is for 2 hours or more.

### Claim 10 (depends on 1)

The process of claim 1, wherein said administering is for 7 hours or more.

### Claim 11 (depends on 1)

The process of claim 1, wherein said administering occurs once daily for 20 or more days.

### Claim 12 (depends on 1)

The process of claim 1, wherein said administering comprises applying the composition to an upper eyelid, a lower eyelid, or both of said subject.

### Claim 13

A process for treatment or prevention of demodex blepharitis in a subject in need thereof comprising:
applying a wipe to an upper eyelid, a lower eyelid, or both of said subject, said wipe comprising:
a woven or non-woven membrane; and
a treatment composition, the treatment composition comprising melatonin, one or more anti-microbial compounds, and optionally one or more pharmaceutically acceptable excipients.

### Claim 14 (depends on 13)

The process of claim 13, wherein said antimicrobial compound comprises hydroxypropyl bis-hydroxyethyldimonium chloride.

### Claim 15 (depends on 13)

The process of claim 13, wherein said process further comprises applying a second composition comprising at least one avermectin compound selected from 5-O-demethyl-22,23-dihydroavermectin A1a or 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, or a combination thereof and melatonin, wherein an aggregate concentration of the avermectin compound is less than 1 wt %.

### Claim 16 (depends on 15)

The process of claim 15, wherein said wipe is applied at time different than the application of said composition.

### Claim 17 (depends on 13)

The process of claim 13, wherein said wipe is applied in the morning, the evening or both.

### Claim 18

A composition for the treatment of demodex blepharitis in a subject comprising:
at least one avermectin compound selected from of 5-O-demethyl-22,23-dihydroavermectin A1a and 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, and melatonin,
wherein an aggregate concentration of the avermectin compound is less than 1 wt %, and optionally further comprising one or more pharmaceutically acceptable excipients.

### Claim 19 (depends on 18)

The composition of claim 18, wherein said melatonin is present at about 0.1 wt % to about 5 wt % 20. The composition of claim 18, wherein the avermectin compound comprises a combination of 5-O-demethyl-22,23-dihydroavermectin A1a and 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a, wherein the combination is about 90 mol % 5-O-demethyl-22,23-dihydroavermectin A1a and about 10 mol % 5-O-demethyl-25-de(1-methylpropyl)-22,23-dihydro-25-(1-methylethyl)avermectin A1a.
